Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 18

981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy

Date

21 Oct 2023

Session

Poster session 18

Topics

Clinical Research;  Multi-Disciplinary and Multi-Professional Cancer Care;  Radiation Oncology;  Image-Guided Therapy

Tumour Site

Hepatobiliary Cancers

Presenters

Ahmad Abdel-Azeez

Citation

Annals of Oncology (2023) 34 (suppl_2): S594-S618. 10.1016/S0923-7534(23)01939-7

Authors

A.M. Abdel-Azeez1, A. Saber2

Author affiliations

  • 1 Clinical Oncology, El Menia University Hospital, 61111 - Al-Minya/EG
  • 2 Clinical Oncology, Minia University, ‎61511 - Al-Minya/EG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 981P

Background

Hepatocellular carcinoma (HCC) has a high incidence and mortality worldwide, particularly in Africa and East Asia, due to the widespread hepatitis B and C viral infections (1). Locally advanced HCC is frequently associated with vascular invasion, commonly affecting the portal vein, with an incidence of portal vein tumor thrombosis (PVTT) ranging from 31.4 to 34% (2). PVTT is associated with poor clinical outcomes, including deterioration of hepatic function, tumor dissemination, and shorter overall survival (3). Treatment options for HCC with PVTT are limited. Radiation therapy (RT) has an important role in the management of HCC, from palliative to curative intent. (4).

Methods

Fifty patients with PVTT in HCC were prospectively treated with IMRT using moderately hypofractionated doses. A statistical analysis of the patient's survival and radiotherapy (RT) response was done. Potential prognostic factors for response to RT and survival were assessed.

Results

The median survival for 50 patients was 10 months, with a 1-year survival rate of 36% and a response rate of 36%. Response to treatment, Eastern Cooperative Oncology Group Performance Status (ECOG PS), hepatic focal lesion size, and Child-Pugh score were statistically significant prognostic factors for survival in univariate analysis (P = <0.001, P = 0.001, P = 0.007, and P = <0.001, respectively). Among these factors, Child-Pugh score, ECOG PS, and response to treatment were significant for patient prognosis in multivariable analysis (P = 0.003, P = 0.012, and P = 0.023, respectively).

Conclusions

As patients with PVTT usually have a poor prognosis and short survival, using hypofractionated RT regimens with short-course treatment can improve survival in these patients. RT responders can be elected for treatment with another local treatment modality with a chance for better overall survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Minia University.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.